Pancreatic tumour cohort

On the US test set, a breakdown by cancer type shows that the AI system's sensitivity advantage is concentrated on the identification of invasive cancers (e.g. invasive lobular/ductal carcinoma) rather than in situ cancer (e.g. ductal carcinoma in situ). See Extended Data Figure 7B. A breakdown by BI-RADS ................
................